Peter Hillmen is Professor of Experimental Hematology and Honorary Consultant Hematologist at the University of Leeds and Leeds Teaching Hospitals NHS Trust.
He qualified in Medicine at Leeds University Medical School in 1985 and completed his general medical training in Leeds in 1988. He then spent 5 years specialising in hematology at the Hammersmith Hospital in London before returning to Leeds. He was appointed Professor of Hematology at the University of Leeds in 2013.
Prof. Hillmen’s research interests include both paroxysmal nocturnal hemoglobinuria (PNH) and chronic lymphocytic leukemia (CLL). His research investigating PNH, which he has conducted since 1990, eventually led to the development of anti-complement therapy for the disease. Furthermore, he was the lead on the trials of eculizumab and is currently leading the National PNH Service based in Leeds and Kings.
Understanding the pathophysiology of CLL and developing novel therapies for the disease has been an interest of his since 1995. His group pioneered the use of measurable residual disease (MRD) assessment in CLL. He also chairs the NCRI CLL subgroup in the UK, which is responsible for the development of UK CLL clinical trials.
Steering Committee member for MRD Focus.